Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Blood and lymphatic system disorders – page 18

  • 1 206 clinical trials
  • 460 recruiting
  • 364 conditions
  • 27 countries

Conditions in this area

364 conditions with trials, the busiest first

Plasma cell myeloma164Acute myeloid leukaemia132Chronic lymphocytic leukaemia80Myelodysplastic syndrome53Diffuse large B-cell lymphoma51Acute lymphocytic leukaemia43Plasma cell myeloma refractory42Follicular lymphoma41Mantle cell lymphoma33Myelofibrosis32B-cell small lymphocytic lymphoma29Chronic myeloid leukaemia29Immune thrombocytopenia27B-cell lymphoma25Factor VIII deficiency25Sickle cell disease25Hodgkin's disease23Non-Hodgkin's lymphoma22Haematological malignancy20Marginal zone lymphoma17Paroxysmal nocturnal haemoglobinuria17B-cell lymphoma refractory16B-cell type acute leukaemia16Anaemia14+340

Clinical trials in Blood and lymphatic system disorders

1 206 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 206 clinical trials

Acute lymphocytic leukaemia

Recruiting

Study Comparing Ponatinib and Imatinib with Chemotherapy for Patients 55+ with Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Blinatumomab
  • Sponsor:Cardiff University

Systemic mastocytosis

Recruiting

Study on Dupilumab and Fexofenadine for Treating Indolent Systemic Mastocytosis with Skin Involvement in Patients

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Dupilumab
  • Sponsor:Medical University Of Gdansk

Diffuse large B-cell lymphoma refractory+2

Recruiting

Study on the Effectiveness and Safety of AZD0486 for Adults with Relapsed or Refractory Non-Hodgkin Lymphoma

InvestigationalNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Human Igg4 Kappa Monoclonal Antibody Against Cd3 And Cd19
  • Sponsor:AstraZeneca AB

Paroxysmal nocturnal haemoglobinuria

Recruiting

Study of Danicopan with Ravulizumab or Eculizumab for Children with Paroxysmal Nocturnal Hemoglobinuria and Extravascular Hemolysis

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:0–17 years
  • Substances:Danicopan
  • Sponsor:Alexion Pharmaceuticals Inc.

Hairy cell leukaemia

Recruiting

Study of Vemurafenib and Rituximab for Untreated Hairy Cell Leukemia Patients

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cladribine
  • Sponsor:Universita Degli Studi Di Perugia

Chronic lymphocytic leukaemia+2

Recruiting

Study of IDP-121 for Patients with Relapsed or Refractory Multiple Myeloma, B-cell Lymphoma, or Chronic Lymphocytic Leukemia

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:IDP-121
  • Sponsor:Idp Discovery Pharma S.L.

Plasma cell leukaemia

Recruiting

Study on the Effectiveness and Safety of Bortezomib and Daratumumab for Patients with Primary Plasma Cell Leukemia

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Hellenic Society Of Hematology

Haematological malignancy+1

Recruiting

Study on the Safety and Effectiveness of SMART101 for Patients Undergoing Stem Cell Transplantation for Blood Cancers

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Allogeneic T-Cell Precursors, Mobilized Peripheral Blood-Derived, Ex Vivo Cultured
  • Sponsor:Smart Immune

Acute myeloid leukaemia

Recruiting

Study on the Effectiveness of Gilteritinib and Drug Combination for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Amsacrine
  • Sponsor:Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.

Acute myeloid leukaemia

Recruiting

Study on Stopping Venetoclax and Azacitidine in Patients with Acute Myeloid Leukemia Who Are Responding to Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Institut Paoli-Calmettes

B-cell type acute leukaemia

Recruiting

Study on Pegaspargase and Rituximab for Treating Children with Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:CroatiaCroatia
  • Participants:0–17 years
  • Substances:Pegaspargase
  • Sponsor:Semmelweis University

Plasma cell myeloma recurrent

Recruiting

Study Comparing Continuous and Fixed Duration Therapy with Daratumumab, Lenalidomide, and Dexamethasone for Patients with Relapsed Multiple Myeloma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Daratumumab
  • Sponsor:Assistance Publique Hopitaux De Paris

Substances studied in this area

The therapies tested most often in Blood and lymphatic system disorders trials.

Dexamethasone139 clinical trialsRituximab121 clinical trialsVenetoclax115 clinical trialsCyclophosphamide99 clinical trialsLenalidomide99 clinical trialsCytarabine77 clinical trialsDaratumumab74 clinical trialsAzacitidine65 clinical trialsBortezomib64 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.